Over the last 50 years, revascularization and pharmacotherapeutic innovations have led to significant reductions in major adverse CV events associated with both acute and chronic coronary diseases. In historic acute MI trials, long-term use of beta-blockers has led to large reductions in major adverse CV events (MACE). These trials laid the foundation for the widespread and often lifelong use of
Pharmacology Consult: GLP-1 receptor agonists for weight loss management healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
A new drug developed by professors from the School of Pharmacy and Pharmaceutical Sciences at Binghamton University has received Food and Drug Administration (FDA) approval for the treatment of patients with Duchenne muscular dystrophy (DMD), a common genetic disease that mostly affects young boys.
FDA Approves Drug to Treat Most Common Genetic Disease miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Pharmacology Consult: Updates on management of acute and recurrent pericarditis healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.